Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

The search for non‐invasive systemic biomarkers of response to PD‐L1/PD‐1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful immunological biomarkers is certainly a challenge, as anti‐cancer immune resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuazo, Miren, Arasanz, Hugo, Bocanegra, Ana, Chocarro, Luisa, Vera, Ruth, Escors, David, Kagamu, Hiroshi, Kochan, Grazyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507340/
https://www.ncbi.nlm.nih.gov/pubmed/32648370
http://dx.doi.org/10.15252/emmm.202012706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507340/
https://www.ncbi.nlm.nih.gov/pubmed/32648370
http://dx.doi.org/10.15252/emmm.202012706

Ejemplares similares